Myocardial injury and coagulopathy in COVID-19: A boon or a bane when using anticoagulation
Myocardial injury and coagulopathy in COVID-19: A boon or a bane when using anticoagulation
CME Unit: 1 Point | 
1 hour | 
16 Feb 2023
Overview
About this course
Angiotensin-converting enzyme 2 (ACE2) is an enzyme that conveys protective effects on the cardiovascular system. However, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein binds to ACE2 receptors in the cells enabling entry of the virus into human tissues. The presence of ACE2 receptors in the myocardium leads to myocardial injury through different mechanisms and produces varied cardiac manifestations. Likewise, hyperinflammation in COVID-19 leads to thrombotic events making coagulopathy one of the leading causes of death in severe COVID-19 disease. This e-learning module summarizes the myocardial injury caused by SARS-CoV-2, coagulopathy, and the use of anticoagulants in the management of COVID-19 disease.
Learning outcomes
Upon completion of the educational activity, health care providers should be able to- Understand the mechanism of cardiac injury and coagulopathy caused by SARS-CoV-2
- Evaluate the use of anticoagulants in COVID-19 infection
Topics covered
- COVID-19 myocardial injury and coagulopathy
- Anticoagulation in COVID-19 infection
1 CME Point Available
- This module is accredited for 1 CME Point for medical practitioners enrolled in The Medical Council of Hong Kong’s Continuing Medical Education Programme for Practising Doctors who are not taking CME for Specialists.
- This module is accredited for both Hong Kong Doctors Union (HKDU) members and non-members
- This module is accredited for 1 CME Point for fellows of the Hong Kong College of Physicians.
- Please note that this module will not earn CME credit for fellows of colleges not listed here.
- A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME points.